![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Corvus Pharmaceuticals’ Investigational COVID-19 Treatment Shows Promise
Corvus Pharmaceuticals’ Investigational COVID-19 Treatment Shows Promise
![Corvus Pharmaceutical logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Corvus-Pharmaceutical-logo.gif?t=1599772579&width=430)
In early results from a phase 1 trial, Corvus Pharmaceuticals’ investigational monoclonal antibody CPI-006 showed promise as a COVID-19 treatment.
All 10 patients who received either a 0.3-mg dose or a 1-mg dose of the drug produced high levels of antibodies to the SARS-CoV-2 virus within seven days of a single infusion. The patients also experienced clinical improvement and experienced no drug-related safety issues.
Corvus is also investigating CPI-006 as an immunotherapy for cancer and infectious disease.
Upcoming Events
-
21Oct